• Keine Ergebnisse gefunden

The EU Medical Device Regulations and Switzerland

N/A
N/A
Protected

Academic year: 2022

Aktie "The EU Medical Device Regulations and Switzerland"

Copied!
2
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

I.

II.

A.

B.

III.

A.

B.

IV.

A.

B.

V.

The EU Medical Device Regulations and Switzerland

Transitional Regime for Swiss and Foreign Manufacturers of Medical Devices

Michael Isler Dr.iur., Rechtsanwalt, Walder Wyss AG, Zürich

Christine Schweikard LL.M., Rechtsanwältin (Rechtsanwaltskammer München), Walder Wyss AG, Zürich

Keyword: Medical Device Law

Table of Contents Introduction Current State

New EU Medical Device Regulations (MDR and IVDR) Swiss-EU Mutual Recognition Agreement (MRA) Position of Swiss Manufacturers

Third Country Status Recommended Measures Position of Swiss Importers

Conformity Under Medical Device Ordinance

“Cassis-De-Dijon” Principle Conclusion

I. Introduction

The Swiss medtech sector is a key factor in the Swiss economy. It accounts for annual sales of 15.8 billion euros, which represents a GDP share of 2.3 percent. Since approximately 70 percent of the business is generated through exports, market access to the members states of the EU as one of the main export markets is pivotal. Swiss manufacturers have enjoyed the benefits of a mutual recognition agreement (MRA) with the European Community, that entered into force on 1 June 2002, for almost two decades.

With the advent of the new EU medical device regulations replacing the pertinent directives in the near…

111 LSR 2/2020 | S. 111-119

1

2

3 4

Verlag

Das Dokument "The EU Medical Device Regulations and Switzerland" wurde von Gast am 09.06.2020 auf der Website lsr.recht.ch erstellt. | © Staempfli Verlag AG, Bern - 2020

(2)

Dieses Dokument ist für Abonnenten oder Pay-per-Document- Kunden zugänglich.

➡ Abonnieren ➡ Kaufen ➡ Kostenlos testen Login

Das Dokument "The EU Medical Device Regulations and Switzerland" wurde von Gast am 09.06.2020 auf der Website lsr.recht.ch erstellt. | © Staempfli Verlag AG, Bern - 2020

Referenzen

ÄHNLICHE DOKUMENTE

For sales packaging, transport packaging and beverage packaging, the share of reused packaging of marketed packaging should increase by at least 15 % by 2025 and 30 % by 2030

Promote reuse through separate reuse targets for tex- tiles, electronics, bulky waste, sales packaging, transport packaging and beverage packaging, and by a compulsory labelling

the extended implementation time- line also applies to Switzerland, as a result of which medical devices may be placed on the EU internal market until 25 May 2021 under the current

This is severely disrupting healthcare / life sciences stakeholders’ efforts to imple- ment the new Medical Device Regulation (MDR), which will replace the current Medical

Given the potentially significant exposure with respect to EU import duties (customs duty and value added tax) the new rules call for a comprehensive re-evaluation of the

The student and receiving institution will communicate to the sending institution any problems or changes regarding the proposed mobility program, responsible persons and/ or

einzelner Investoren gewertet werden, was abzulehnen ist. CETA enthält für Inländerbehandlung und Meistbegünstigung Ausnahmeklauseln, die dem GATT und dem GATS entnommen sind. Es

A Brief History of European Medicinal Products Regulation..C. Current EU Structures and Procedures for Regulating